Teva Pharmaceutical Industries (TEVA)
(Real Time Quote from BATS)
$17.08 USD
+0.27 (1.61%)
Updated Jul 22, 2024 02:53 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Teva Pharmaceutical Industries Ltd. (TEVA) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$18.50 | $24.00 | $11.00 | 10.05% |
Price Target
Based on short-term price targets offered by eight analysts, the average price target for Teva Pharmaceutical Industries Ltd. comes to $18.50. The forecasts range from a low of $11.00 to a high of $24.00. The average price target represents an increase of 10.05% from the last closing price of $16.81.
Analyst Price Targets (8 )
Broker Rating
Teva Pharmaceutical Industries Ltd. currently has an average brokerage recommendation (ABR) of 1.40 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 10 brokerage firms. The current ABR compares to an ABR of 1.44 a month ago based on nine recommendations.
Of the 10 recommendations deriving the current ABR, eight are Strong Buy, representing 80% of all recommendations. A month ago, Strong Buy represented 77.78%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TEVA.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 8 | 8 | 7 | 7 | 7 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 2 | 2 | 2 | 2 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.40 | 1.40 | 1.44 | 1.44 | 1.60 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/10/2024 | Argus Research Corp. | Jasper Hellweg | Not Available | Strong Buy |
7/10/2024 | UBS | Ashwani Verma | Strong Buy | Strong Buy |
5/13/2024 | Piper Sandler | David Amsellem | Strong Buy | Strong Buy |
5/9/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
5/7/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
3/15/2024 | Evercore Partners | Umer Raffat | Strong Buy | Strong Buy |
2/5/2024 | Goldman Sachs | Nathan Rich | Hold | Hold |
12/18/2023 | Not Identified | Not Identified | Not Available | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.40 |
ABR (Last week) | 1.40 |
# of Recs in ABR | 10 |
Average Target Price | $18.50 |
LT Growth Rate | 4.60% |
Industry | Medical - Generic Drugs |
Industry Rank by ABR | 96 of 252 |
Current Quarter EPS Est: | 0.57 |